Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced in May 2022 the appointment of Professor Bernhardt L. Trout, Raymond F. Baddour, ScD, (1949) Professor of Chemical Engineering, as a member to the Company´s Scientific Advisory Board (SAB). Professor Trout is an internationally renowned, highly experienced professional on sophisticated computational, theoretical, and experimental methods in order to probe complex chemical systems on the molecular level. With the appointment of Professor Trout, Leukocare will further broaden its expertise in machine learning and biopharmaceutical formulation development.

Dr. Andreas Seidl, Chief Operating Officer at Leukocare, commented, “We are very proud to welcome Professor Trout to Leukocare’s SAB. Drawing on his vast scientific expertise on molecular engineering, he will support our activities in machine learning and prediction of stability to accelerate and enhance the development of stable biopharmaceutical formulations. We very much look forward to our cooperation and scientific exchange.” Professor Trout focuses his research on the development of advanced manufacturing processes and rational tools for formulation and product design, primarily liquid formulations, but also lyophilized formulations. A major aspect of his work relates to the development of both microscopic and macroscopic models to design stable formulations efficiently. Together with colleagues from MIT, he set-up the Novartis-MIT Center for Continuous Manufacturing in 2007 which until 2019 actively pursued the objective of transforming pharmaceutical production.

Leukocare’s SAB now comprises of Professor Johannes Buchner, Ph.D., Technical University of Munich, Germany; Professor Paul Dalby, Ph.D., University College London, United Kingdom; Professor Ulrike Protzer, Ph.D., Technical University of Munich, Germany; Professor Theodore Randolph, University of Colorado, Boulder, USA, and Professor Bernhardt. L. Trout, Massachusetts Institute of Technology, USA. The SAB works closely with the scientific management team to help grow the technology strategy portfolio of Leukocare and to advise 2 on current and future research activities. Further information can be found on the Company’s website at www.leukocare.com/who-we-are/scientific-advisory-board.